A Phase 2 interventional study of etafilcon A with ketotifen and 1-Day ACUVUE in Visual Acuity, sponsored by Johnson & Johnson Vision Care, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-17.
Sponsored by Johnson & Johnson Vision Care, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This clinical study is a randomized, double-masked, bilateral, controlled, two-arm parallel group, multi-site, 1-Week, 2-visit dispensing study. Subjects between the ages of 18-40 will be randomized into a placebo arm or an investigational K-Lens arm.
Johnson & Johnson Vision Care, Inc. is the lead sponsor of 221 studies on the registry; 1 is open to participants now.
Of its 111 completed or terminated interventional studies of FDA-regulated products, 103 (93%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Potential subjects must satisfy all of the following criteria to be enrolled in the study
Exclusion Criteria:
Potential subjects who meet any of the following criteria will be excluded from participating in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
etafilcon A with ketotifen. Subjects between the ages of 18-40 will be randomized into the K-Lens arm and will be scheduled for a total of two study visits with approximately 6-9 days in between.
Combination Product: etafilcon A with ketotifen
1-Day Acuvue. Subjects between the ages of 18-40 will be randomized into the Placebo arm and will be scheduled for a total of two study visits with approximately 6-9 days in between.
Device: 1-Day ACUVUE
Drug page: KetotifenStudies of KetotifenKetotifen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Etafilcon A with ketotifen
1-Day ACUVUE
Monocular Contact Lens-corrected Distance Visual Acuity (Per-Protocol Population)
Monocular contact lens-corrected distance visual acuity was assessed using a logMAR visual acuity scale. This was evaluated for each eye, under high luminance and high contrast conditions at 4 meters from ETDRS charts. Distance visual acuity was reported by lens type and visit.
Time frame: Baseline (Visit 1) and 1-week follow up (Visit 2)
Monocular Contact Lens-corrected Distance Visual Acuity (Modified Intent-to-Treat Population)
Monocular contact lens-corrected distance visual acuity was assessed using a logMAR visual acuity scale. This was evaluated for each eye, under high luminance and high contrast conditions at 4 meters from ETDRS charts. Distance visual acuity was reported by lens type and visit.
Time frame: Baseline (Visit 1) and 1-week follow up (Visit 2)
The Number of Eyes With Clinically Significant Slit Lamp Findings
Slit lamp findings were assessed using a biomicroscope for each subject eye at all scheduled and unscheduled visits. Clinical significant slit lamp findings are defined as Grade 3 or Grade 4. (Grade 0=None, Grade 1=Trace, Grade 2=Mild, Grade 3=Moderate and Grade 4= Severe). The data was dichotomized as 1=Grade 3 or Grade 4 and 0, otherwise. The number of eyes with clinically significant slit lamp findings for each lens type was reported.
Time frame: Up to 1-Week Follow-up
The Number of Eyes With Unacceptable Lens Fitting
Lens fit was assessed for each subject and eye using a biomicroscope. Unacceptable lens fit was assessed at all scheduled and unscheduled visits. A subject was deemed to have an unacceptable lens fitting if they met any of the following criteria: (1) Limbal exposure at primary gaze with extreme eye movement, (2) edge lift, (3) excessive movement in primary up gaze, (4) insufficient movement in all three of the following conditions: primary gaze, up gaze and push up test. The number of eyes with unacceptable lens fitting was reported for each lens type.
Time frame: Up to 1-Week Follow-up
| Milestone | Etafilcon A With Ketotifen | Etafilcon A |
|---|---|---|
| Started | 94 | 47 |
| Completed | 93 | 47 |
| Not completed | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
Monocular contact lens-corrected distance visual acuity was assessed using a logMAR visual acuity scale. This was evaluated for each eye, under high luminance and high contrast conditions at 4 meters from ETDRS charts. Distance visual acuity was reported by lens type and visit.
| logMAR | Etafilcon A With Ketotifen | Etafilcon A |
|---|---|---|
| Visit 1 (Baseline) | -0.111 ± 0.0702 | -0.109 ± 0.0809 |
| Visit 2 (1-week follow up) | -0.115 ± 0.0717 | -0.118 ± 0.0814 |
Monocular contact lens-corrected distance visual acuity was assessed using a logMAR visual acuity scale. This was evaluated for each eye, under high luminance and high contrast conditions at 4 meters from ETDRS charts. Distance visual acuity was reported by lens type and visit.
| logMAR | Etafilcon A With Ketotifen | Etafilcon A |
|---|---|---|
| Visit 1 (Baseline) | -0.109 ± 0.0740 | -0.110 ± 0.0806 |
| Visit 2 (1-week follow up) | -0.115 ± 0.0717 | -0.117 ± 0.0815 |
Slit lamp findings were assessed using a biomicroscope for each subject eye at all scheduled and unscheduled visits. Clinical significant slit lamp findings are defined as Grade 3 or Grade 4. (Grade 0=None, Grade 1=Trace, Grade 2=Mild, Grade 3=Moderate and Grade 4= Severe). The data was dichotomized as 1=Grade 3 or Grade 4 and 0, otherwise. The number of eyes with clinically significant slit lamp findings for each lens type was reported.
| Number of Eyes | Etafilcon A With Ketotifen | Etafilcon A |
|---|---|---|
| The Number of Eyes With Clinically Significant Slit Lamp Findings | 0 | 0 |
Lens fit was assessed for each subject and eye using a biomicroscope. Unacceptable lens fit was assessed at all scheduled and unscheduled visits. A subject was deemed to have an unacceptable lens fitting if they met any of the following criteria: (1) Limbal exposure at primary gaze with extreme eye movement, (2) edge lift, (3) excessive movement in primary up gaze, (4) insufficient movement in all three of the following conditions: primary gaze, up gaze and push up test. The number of eyes with unacceptable lens fitting was reported for each lens type.
| eyes | Etafilcon A With Ketotifen | Etafilcon A |
|---|---|---|
| The Number of Eyes With Unacceptable Lens Fitting | 0 | 1 |
Collected over Throughout the entire duration of the study. Approximately 1-Week per subject.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Etafilcon A With Ketotifen | 0/94 (0%) | 0/94 (0%) | 0/94 (0%) |
| Etafilcon A | 0/47 (0%) | 0/47 (0%) | 0/47 (0%) |
All subjects that were dispensed a study lens.
| Age, Continuous(years) | Etafilcon A With Ketotifen | Etafilcon A | Total |
|---|---|---|---|
| Mean | 30.4 ± 4.98 | 29.6 ± 4.56 | 30.1 ± 4.84 |
| Sex: Female, Male(Participants) | Etafilcon A With Ketotifen | Etafilcon A | Total |
|---|---|---|---|
| Female | 59 | 31 | 90 |
| Male | 35 | 16 | 51 |
| Race/Ethnicity, Customized(Participants) | Etafilcon A With Ketotifen | Etafilcon A | Total |
|---|---|---|---|
| Asian | 4 | 1 | 5 |
| Black or African American | 7 | 3 | 10 |
| White | 83 | 43 | 126 |
| Region of Enrollment(participants) | Etafilcon A With Ketotifen | Etafilcon A | Total |
|---|---|---|---|
| United States | 94 | 47 | 141 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2017 to primary completion in Feb 2018, 2 months.
Results were first posted in Mar 2021, 3 years 1 month after primary completion. A results delay was requested in Feb 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ketotifen
Johnson & Johnson Vision Care, Inc. →